A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy

Trial Profile

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Eleclazine (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Pharmacodynamics; Registrational
  • Acronyms LIBERTY-HCM
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 24 Feb 2017 Status changed from active, no longer recruiting to discontinued.
    • 01 Feb 2017 This trial was discontinued in Netherlands, according to European Clinical Trials Database.
    • 25 Jan 2017 This trial was completed in Italy (end date: 2016-12-08), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top